Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Inflammation
Published in: Journal of Inflammation 1/2017

Open Access 01-12-2017 | Review

Regulating STING in health and disease

Authors: Yang Li, Heather L. Wilson, Endre Kiss-Toth

Published in: Journal of Inflammation | Issue 1/2017

Login to get access

Abstract

The presence of cytosolic double-stranded DNA molecules can trigger multiple innate immune signalling pathways which converge on the activation of an ER-resident innate immune adaptor named “STimulator of INterferon Genes (STING)”. STING has been found to mediate type I interferon response downstream of cyclic dinucleotides and a number of DNA and RNA inducing signalling pathway. In addition to its physiological function, a rapidly increasing body of literature highlights the role for STING in human disease where variants of the STING proteins, as well as dysregulated STING signalling, have been implicated in a number of inflammatory diseases. This review will summarise the recent structural and functional findings of STING, and discuss how STING research has promoted the development of novel therapeutic approaches and experimental tools to improve treatment of tumour and autoimmune diseases.
Literature
1.
2.
Zheng M, Zheng M, Xie L, Xie L, Liang Y, Wu S, et al. Recognition of cytosolic DNA attenuates glucose metabolism and induces AMPK mediated energy stress response. Int J Biol Sci. 2015;11:587–94.PubMedPubMedCentralCrossRef
3.
4.
5.
6.
7.
8.
Zhong B, Yang Y, Li S, Wang YY, Li Y, Diao F, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity. 2008;29:538–50.PubMedCrossRef
9.
10.
Abe T, Harashima A, Xia T, Konno H, Konno K, Morales A, et al. STING Recognition of cytoplasmic DNA instigates cellular defense. Mol Cell. 2013;50:5–15.PubMedCrossRef
11.
12.
Lakkaraju AK, Abrami L, Lemmin T, Blaskovic S, Kunz B, Kihara A, et al. Palmitoylated calnexin is a key component of the ribosome–translocon complex. EMBO J. 2012;31:1823–35.PubMedPubMedCentralCrossRef
13.
Nagasawa K, Higashi T, Hosokawa N, Kaufman RJ, Nagata K. Simultaneous induction of the four subunits of the TRAP complex by ER stress accelerates ER degradation. EMBO Rep. 2007;8:483–9.PubMedPubMedCentralCrossRef
14.
Ishikawa H, Barber GN. The STING pathway and regulation of innate immune signaling in response to DNA pathogens. Cell Mol Life Sci. 2011;68:1157–65.PubMedCrossRef
15.
16.
17.
18.
19.
20.
21.
22.
23.
Liu Y, Goulet M-L, Sze A, Bel Hadj S, Belgnaoui SM, Lababidi RR, et al. RIG-I Mediated STING Up-Regulation Restricts HSV-1 Infection. J Virol. 2016;. doi:10.​1128/​JVI.​00748-16.
24.
25.
26.
Paijo J, Döring M, Spanier J, Grabski E, Nooruzzaman M, Schmidt T, et al. cGAS senses human cytomegalovirus and induces type I interferon responses in human monocyte-derived cells. PLoS Pathog. 2016;12(4):e1005546.
27.
Dell’Oste V, Gatti D, Gugliesi F, De Andrea M, Bawadekar M, Lo Cigno I, et al. Innate nuclear sensor IFI16 translocates into the cytoplasm during the early stage of in vitro human cytomegalovirus infection and is entrapped in the egressing virions during the late stage. J Virol. 2014;88:6970–82. doi:10.​1128/​JVI.​00384-14.PubMedPubMedCentralCrossRef
28.
29.
30.
31.
32.
Koppe U, Högner K, Doehn J-M, Müller HC, Witzenrath M, Gutbier B, et al. Streptococcus pneumoniae stimulates a STING- and IFN regulatory factor 3-dependent type I IFN production in macrophages, which regulates RANTES production in macrophages, cocultured alveolar epithelial cells, and mouse lungs. J Immunol. 2012;188:811–7. doi:10.​4049/​jimmunol.​1004143.PubMedCrossRef
33.
Gratz N, Hartweger H, Matt U, Kratochvill F, Janos M, Sigel S, et al. Type I interferon production induced by streptococcus pyogenes-derived nucleic acids is required for host protection. PLoS Pathog. 2011;7:1–16.CrossRef
34.
Gries CM, Bruger EL, Moormeier DE, Scherr TD, Waters CM, Kielian T. Cyclic di-AMP released from Staphylococcus aureus biofilm induces a macrophage type I interferon response. Infect Immun. 2016. doi:10.​1128/​IAI.​00447-16.
35.
36.
37.
Davies BW, Bogard RW, Young TS, Mekalanos JJ. Coordinated regulation of accessory genetic elements produces cyclic di-nucleotides for V. cholerae virulence. Cell. 2012;149:358–70.PubMedPubMedCentralCrossRef
38.
Nazmi A, Mukhopadhyay R, Dutta K, Basu A. STING mediates neuronal innate immune response following Japanese encephalitis virus infection. Sci Rep. 2012;2:1–10.CrossRef
39.
40.
41.
42.
Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MYK, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41:830–42.PubMedPubMedCentralCrossRef
43.
Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:543–852.PubMedPubMedCentralCrossRef
44.
45.
York AG, Williams KJ, Argus JP, Zhou QD, Brar G, Vergnes L, et al. Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling. Cell. 2015;163:1716–29.PubMedPubMedCentralCrossRef
46.
47.
Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature. 2011;478:515–8.PubMedPubMedCentralCrossRef
48.
49.
Collins AC, Cai H, Li T, Franco LH, Li XD, Nair VR, et al. Cyclic GMP-AMP synthase Is an innate immune DNA sensor for mycobacterium tuberculosis. Cell Host Microbe. 2015;17(6):820–828.
50.
Barker JR, Koestler BJ, Carpenter VK, Burdette DL, Waters CM, Vance RE, et al. STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection. MBio. 2013;4
51.
52.
53.
Gao P, Ascano M, Zillinger T, Wang W, Dai P, Serganov AA, et al. Structure-function analysis of STING activation by c[G(2′,5′) pA(3′,5′)p] and targeting by antiviral DMXAA. Cell. 2013;154:748–62.PubMedPubMedCentralCrossRef
54.
Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M, et al. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep. 2013;3:1355–61.PubMedPubMedCentralCrossRef
55.
Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, et al. Cyclic GMP-AMP containing mixed Phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell. 2013;51:226–35.PubMedCrossRef
56.
57.
58.
Lippmann J, Rothenburg S, Deigendesch N, Eitel J, Meixenberger K, Van Laak V, et al. IFN?? responses induced by intracellular bacteria or cytosolic DNA in different human cells do not require ZBP1 (DLM-1/DAI). Cell Microbiol. 2008;10:2579–88.PubMedCrossRef
59.
Lee KG, Kim SSY, Kui L, Voon DCC, Mauduit M, Bist P, et al. Bruton’s tyrosine kinase phosphorylates DDX41 and activates its binding of dsDNA and STING to initiate type 1 interferon response. Cell Rep. 2015;10:1055–65.PubMedCrossRef
60.
61.
Kerur N, Veettil MV, Sharma-Walia N, Bottero V, Sadagopan S, Otageri P, et al. IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection. Cell Host Microbe. 2011;9:363–75.PubMedPubMedCentralCrossRef
62.
Roy A, Dutta D, Iqbal J, Pisano G, Gjyshi O, Ansari MA, et al.. Nuclear innate immune DNA sensor IFI16 is degraded during lytic reactivation of Kaposi’s Sarcoma-Associated Herpesvirus (KSHV): role of IFI16 in maintenance of KSHV latency. J Virol. 2016. doi:10.​1128/​JVI.​01003-16.
63.
Li T, Chen J, Cristea IM. Human cytomegalovirus tegument protein pUL83 inhibits IFI16-mediated DNA sensing for immune evasion. Cell Host Microbe. 2013;14:591–9.PubMedCrossRef
64.
Diner BA, Lum KK, Toettcher JE, Cristea IM. Viral DNA Sensors IFI16 and cyclic GMP-AMP synthase possess distinct functions in regulating viral gene expression, immune defenses, and apoptotic responses during herpesvirus infection. MBio. 2016;7:1–15.CrossRef
65.
Orzalli MH, Broekema NM, Diner BA, Hancks DC, Elde NC, Cristea IM, et al. cGAS-mediated stabilization of IFI16 promotes innate signaling during herpes simplex virus infection. Proc Natl Acad Sci. 2015. doi:10.​1073/​pnas.​1424637112.
66.
Almine JF, Hare CAJO, Dunphy G, Haga IR, Naik RJ, Atrih A, et al. STING during DNA sensing in human keratinocytes. Nat Commun. 2017;8
67.
Guo H, König R, Deng M, Riess M, Mo J, Zhang L, et al. NLRX1 sequesters STING to negatively regulate the interferon response, thereby facilitating the replication of HIV-1 and DNA viruses. Cell Host Microbe. 2016;19:515–28.PubMedPubMedCentralCrossRef
68.
Gao D, Wu J, Wu Y-T, Du F, Aroh C, Yan N, et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science. 2013;341:903–6.PubMedCrossRef
69.
Barouch DH, Ghneim K, Bosche WJ, Li Y, Berkemeier B, Hull M, et al. Rapid inflammasome activation following mucosal SIV infection of rhesus monkeys. Cell. 2016;165:656–67.PubMedPubMedCentralCrossRef
70.
Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol. 2005;6:981–8. doi:10.​1038/​ni1243.PubMedCrossRef
71.
Xu L-G, Wang Y-Y, Han K-J, Li L-Y, Zhai Z, Shu H-B. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell. 2005;19:727–40.PubMedCrossRef
72.
Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005;437:1167–72.PubMedCrossRef
73.
Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kB and IRF3. Cell. 2005;122:669–82.PubMedCrossRef
74.
75.
Vance JE. MAM (mitochondria-associated membranes) in mammalian cells: Lipids and beyond. Biochim Biophys Acta. 1841;2014:595–609.
76.
77.
Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol. 2009;10:1065–72.PubMedCrossRef
78.
Chiu YH, MacMillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell. 2009;138:576–91.PubMedPubMedCentralCrossRef
79.
Saitoh T, Fujita N, Hayashi T, Takahara K, Satoh T, Lee H, et al. Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. Proc Natl Acad Sci U S A. 2009;106:20842–6. doi:10.1073/pnas.0911267106\r0911267106.
80.
Rasmussen SB, Horan KA, Holm CK, Stranks AJ, Mettenleiter TC, Simon AK, et al. Activation of autophagy by α-herpesviruses in myeloid cells is mediated by cytoplasmic viral DNA through a mechanism dependent on stimulator of IFN genes. J Immunol. 2011;187:5268–76. doi:10.​4049/​jimmunol.​1100949.PubMedPubMedCentralCrossRef
81.
Watson RO, Manzanillo PS, Cox JS. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell. 2012;150:803–15.PubMedPubMedCentralCrossRef
82.
83.
Tsuchida T, Zou J, Saitoh T, Kumar H, Abe T, Matsuura Y, et al. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity. 2010;33:765–76.PubMedCrossRef
84.
Clark K, Plater L, Peggie M, Cohen P. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IκB kinase ε. J Biol Chem. 2009;284:14136–46.
85.
Kishore N, Huynh QK, Mathialagan S, Hall T, Rouw S, Creely D, et al. IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK-2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2. J Biol Chem. 2002;277:13840–7.
86.
Uzé G, Schreiber G, Piehler J, Pellegrini S. The receptor of the type I interferon family. Curr Top Microbiol Immunol. 2007;316:71–95.PubMed
87.
Gauzzi MC, Velazquez L, McKendry R, Mogensen KE, Fellous M, Pellegrini S. Interferon-??-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J Biol Chem. 1996;271:20494–500.PubMedCrossRef
88.
Prchal-Murphy M, Semper C, Lassnig C, Wallner B, Gausterer C, Teppner-Klymiuk I, et al. TYK2 kinase activity is required for functional type I interferon responses in vivo. PLoS One. 2012;7
89.
Li X, Leung S, Qureshi S, Darnell JE, Stark GR. Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-?? J Biol Chem. 1996;271:5790–4.PubMedCrossRef
90.
91.
Thompson MR, Sharma S, Atianand M, Jensen SB, Carpenter S, Knipe DM, et al. Interferon γ-inducible protein (IFI) 16 transcriptionally regulates type I interferons and other interferon-stimulated genes and controls the interferon response to both DNA and RNA viruses. J Biol Chem. 2014;289:23568–81.PubMedPubMedCentralCrossRef
92.
Burdette DL, Vance RE. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol. 2013;14(1):19–26. doi:10.​1038/​ni.​2491.
93.
Jin L, Waterman PM, Jonscher KR, Short CM, Reisdorph NA, Cambier JC. MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals. Mol Cell Biol. 2008;28:5014–26.PubMedPubMedCentralCrossRef
94.
95.
96.
97.
98.
99.
Lou YC, Kao YF, Chin KH, Chen JK, Tu J Le, Chen C, et al. Backbone resonance assignments of the 54??kDa dimeric C-terminal domain of murine STING in complex with DMXAA. Biomol NMR Assign 2014;9:271–274.
100.
Tsuchiya Y, Jounai N, Takeshita F, Ishii KJ, Mizuguchi K. Ligand-induced ordering of the C-terminal tail primes STING for phosphorylation by TBK1. EBioMedicine. 2016;9:87–96.
101.
102.
Konno H, Konno K, Barber GN. XCyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell. 2013;155
103.
Tang ED, Wang CY. Single amino acid change in STING leads to constitutive active signaling. PLoS One. 2015;10
104.
Yi G, Brendel VP, Shu C, Li P, Palanathan S, Cheng KC. Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One. 2013;8
105.
106.
Patel S, Blaauboer SM, Tucker HR, Mansouri S, Ruiz-Moreno JS, Hamann L, et al. The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele. J Immunol. 2016. doi:10.​4049/​jimmunol.​1601585.
107.
Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, et al. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog. 2012;8
108.
Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124:5516–20.PubMedPubMedCentralCrossRef
109.
Yu CY, Chang TH, Liang JJ, Chiang RL, Lee YL, Liao CL, et al. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog. 2012;8
110.
111.
Sauer JD, Sotelo-Troha K, Von Moltke J, Monroe KM, Rae CS, Brubaker SW, et al. The N-ethyl-N-nitrosourea-induced goldenticket mouse mutant reveals an essential function of sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun. 2011;79:688–94.PubMedCrossRef
112.
Wang Y, Lian Q, Yang B, Yan S, Zhou H, He L, et al. TRIM30α is a negative-feedback regulator of the intracellular DNA and DNA virus-triggered response by targeting STING. PLoS Pathog. 2015;11
113.
Wang Q, Liu X, Cui Y, Tang Y, Chen W, Li S, et al. The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. Immunity. 2014;41:919–33.PubMedCrossRef
114.
Zhong B, Zhang L, Lei C, Li Y, Mao AP, Yang Y, et al. The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA. Immunity. 2009;30:397–407.PubMedCrossRef
115.
Marchi S, Patergnani S, Pinton P. The endoplasmic reticulum-mitochondria connection: one touch, multiple functions. Biochim Biophys Acta Bioenerg. 1837;2014:461–9.
116.
Chen H, Sun H, You F, Sun W, Zhou X, Chen L, et al. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell. 2011;147:436–46.PubMedCrossRef
117.
Liu S, Cai X, Wu J, Cong Q, Chen X, Li T, et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science (80- ). 2015;347:aaa2630. doi:10.​1126/​science.​aaa2630.CrossRef
118.
Zhang L, Mo J, Swanson KV, Wen H, Petrucelli A, Gregory SM, et al. NLRC3, a member of the NLR family of proteins, is a negative regulator of innate immune signaling induced by the DNA sensor STING. Immunity. 2014;40:329–41.PubMedPubMedCentralCrossRef
119.
120.
Bai Y, Yang J, Zarrella TM, Zhang Y, Metzger DW, Bai G. Cyclic Di-AMP impairs potassium uptake mediated by a cyclic Di-AMP binding protein in streptococcus pneumoniae. J Bacteriol. 2014;196:614–23.PubMedPubMedCentralCrossRef
121.
Christen M, Christen B, Folcher M, Schauerte A, Jenal U. Identification and characterization of a cyclic di-GMP-specific phosphodiesterase and its allosteric control by GTP. J Biol Chem. 2005;280:30829–37.PubMedCrossRef
122.
Schmidt AJ, Ryjenkov DA, Gomelsky M. The ubiquitous protein domain EAL is a cyclic diguanylate-specific phosphodiesterase: Enzymatically active and inactive EAL domains. J Bacteriol. 2005;187:4774–81.PubMedPubMedCentralCrossRef
123.
124.
Dey RJ, Dey B, Zheng Y, Cheung LS, Zhou J, Sayre D, P Kumar, H Guo, Gyanu Lamichhane HOS& WRB. Deletion of the cyclic di-AMP phosphodiesterase gene (cnpB) in mycobacterium tuberculosis leads to reduced virulence in a mouse model of infection. Mol Microbiol. 2014;93:65–79
125.
Dey RJ, Dey B, Zheng Y, Cheung LS, Zhou J, Sayre D, et al. Inhibition of innate immune cytosolic surveillance by an M. tuberculosis phosphodiesterase. Nat Publ Gr. 2016;13. doi:10.​1038/​nchembio.​2254.
126.
Manikandan K, Sabareesh V, Singh N, Saigal K, Mechold U, Sinha KM. Two-step synthesis and hydrolysis of cyclic di-AMP in mycobacterium tuberculosis. PLoS One. 2014;9
127.
128.
Zhang Z, Bao M, Lu N, Weng L, Yuan B, Liu YJ. The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat Immunol. 2013;14:172–8. doi:10.​1038/​ni.​2492.PubMedCrossRef
129.
Liang Q, Seo GJ, Choi YJ, Kwak MJ, Ge J, Rodgers MA, et al. Crosstalk between the cGAS DNA sensor and beclin-1 autophagy protein shapes innate antimicrobial immune responses. Cell Host Microbe. 2014;15:228–38.PubMedPubMedCentralCrossRef
130.
131.
Flück C, Smith T, Beck HP, Irion A, Betuela I, Alpers MP, et al. Strain-specific humoral response to a polymorphic malaria vaccine. Infect Immun. 2004;72:6300–5.PubMedPubMedCentralCrossRef
132.
133.
van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2–17.PubMed
134.
Benveniste EN, Nguyen VT, Wesemann DR. Molecular regulation of CD40 gene expression in macrophages and microglia. Brain Behav Immun. 2004;18:7–12.PubMedCrossRef
135.
Yao X, Wu J, Lin M, Sun W, He X, Gowda C, et al. Increased CD40 expression enhances early STING-mediated type i interferon response and host survival in a rodent malaria model. PLoS Pathog. 2016;12
136.
137.
Yi G, Wen Y, Shu C, Han Q, Konan K V, Li P, et al. The hepatitis C virus NS4B can suppress STING accumulation to evade innate immune responses. J Virol. 2015. doi:10.​1128/​JVI.​01720-15.
138.
Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, et al. Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. Hepatology. 2013;57:46–58.PubMedCrossRef
139.
Cuchet-Lourenco D, Vanni E, Glass M, Orr A, Everett RD. Herpes simplex virus 1 ubiquitin ligase ICP0 INTERACTS with PML isoform I and induces its SUMO-independent degradation. J Virol. 2012;86:11209–22.PubMedPubMedCentralCrossRef
140.
Maringer K, Fernandez-Sesma A. Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection. Cytokine Growth Factor Rev. 2014;25:669–79.PubMedPubMedCentralCrossRef
141.
Sunthamala N, Thierry F, Teissier S, Pientong C, Kongyingyoes B, Tangsiriwatthana T, et al. E2 proteins of high risk human papillomaviruses down-modulate STING and IFN-?? transcription in keratinocytes. PLoS One. 2014;9
142.
143.
Liu Y, Li J, Chen J, Li Y, Wang W, Du X, et al. Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways. J Virol. 2015;89:2287–300.PubMedCrossRef
144.
145.
Wu JJ, Li W, Shao Y, Avey D, Fu B, Gillen J, et al. Inhibition of cGAS DNA sensing by a herpesvirus virion protein. Cell Host Microbe. 2015;18:333–44.PubMedPubMedCentralCrossRef
146.
Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, et al. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity. 2013;39:1132–42.PubMedCrossRef
147.
Christensen MH, Jensen SB, Miettinen JJ, Luecke S, Prabakaran T, Reinert LS, et al. HSV-1 ICP27 targets the TBK1 -activated STING signalsome to inhibit virus-induced type I IFN expression. EMBO J. 2016;35:1385–99.PubMedCrossRef
148.
Kamga I, Kahi S, Develioglu L, Lichtner M, Marañón C, Deveau C, et al. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis. 2005;192:303–10. doi:10.​1086/​430931.PubMedCrossRef
149.
Harman AN, Lai J, Turville S, Samarajiwa S, Gray L, Marsden V, et al. HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production. Blood. 2011;118:298–308.PubMedPubMedCentralCrossRef
150.
151.
Doyle T, Goujon C, Malim MH. HIV-1 and interferons: who’s interfering with whom? Nat Rev Microbiol. 2015;13:403–13.PubMedCrossRef
152.
153.
154.
155.
Gough DJ, Messina NL, Clarke CJP, Johnstone RW, Levy DE. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity. 2012;36:166–74.PubMedPubMedCentralCrossRef
156.
157.
de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 2001;69:912–20.PubMed
158.
159.
160.
Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003;8:237–49.PubMedCrossRef
161.
162.
163.
164.
165.
Su KY, Pisetsky DS. The role of extracellular DNA in autoimmunity in SLE. Scand J Immunol. 2009;70:175–83.PubMedCrossRef
166.
167.
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James J a, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–33. doi:10.​1056/​NEJMoa021933.PubMedCrossRef
168.
Rahman AH, Eisenberg RA. The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol. 2006;28:131–43.PubMedCrossRef
169.
Enevold C, Kjær L, Nielsen CH, Voss A, Jacobsen RS, Hermansen MLF, et al. Genetic polymorphisms of dsRNA ligating pattern recognition receptors TLR3, MDA5, and RIG-I. Association with systemic lupus erythematosus and clinical phenotypes. Rheumatol Int. 2014;34:1401–8.PubMedCrossRef
170.
Zhang W, Zhou Q, Xu W, Cai Y, Yin Z, Gao X, et al. DNA-dependent activator of interferon-regulatory factors (DAI) promotes lupus nephritis by activating the calcium pathway. J Biol Chem. 2013;288:13534–50.PubMedPubMedCentralCrossRef
171.
172.
de Vries B, Steup-Beekman GM, Haan J, Bollen EL, Luyendijk J, Frants RR, et al. TREX1 gene variant in neuropsychiatric systemic lupus erythematosus. Ann Rheum Dis. 2010;69:1886–7.PubMedCrossRef
173.
Martínez Valle F, Balada E, Ordi-Ros J, Vilardell-Tarres M. DNase 1 and systemic lupus erythematosus. Autoimmun Rev. 2008;7:359–63.PubMedCrossRef
174.
Ding L, Dong G, Zhang D, Ni Y, Hou Y. The regional function of cGAS/STING signal in multiple organs: one of culprit behind systemic lupus erythematosus? Med Hypotheses. 2015;85:846–9.PubMedCrossRef
175.
176.
177.
178.
179.
180.
Maelfait J, Bridgeman A, Benlahrech A, Cursi C, Rehwinkel J. Restriction by SAMHD1 limits cGAS/STING-dependent innate and adaptive immune responses to HIV-1. Cell Reports. 2016;16(6):1492–1501.
181.
Mackenzie KJ, Carroll P, Lettice L, Revuelta A, Abbondati E, Rigby RE, et al. Ribonuclease H2 mutations induce a cGAS / STING- dependent innate immune response. EMBO J. 2016;35:1–14.CrossRef
182.
Pokatayev V, Hasin N, Chon H, Cerritelli SM, Sakhuja K, Ward JM, et al. RNase H2 catalytic core Aicardi-Goutieres syndrome-related mutant invokes cGAS-STING innate immune-sensing pathway in mice. J Exp Med. 2016;213:329–36.PubMedPubMedCentralCrossRef
183.
Oda H, Nakagawa K, Abe J, Awaya T, Funabiki M, Hijikata A, et al. Aicardi-goutières syndrome is caused by IFIH1 mutations. Am J Hum Genet. 2014;95:121–5.PubMedPubMedCentralCrossRef
184.
185.
186.
187.
Günther C, Berndt N, Wolf C, Lee-Kirsch MA. Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3′ repair exonuclease 1 ( TREX1 ). JAMA Dermatol. 2014;1–6. doi:10.​1001/​jamadermatol.​2014.​3438.
188.
Günther C, Meurer M, Stein A, Viehweg A, Lee-Kirsch MA. Familial chilblain lupus - A monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1. Dermatology. 2009;219:162–6.PubMedCrossRef
189.
Ravenscroft JC, Suri M, Rice GI, Szynkiewicz M, Crow YJ. Autosomal dominant inheritance of a heterozygous mutation in SAMHD1 causing familial chilblain lupus. Am J Med Genet Part A. 2011;155:235–7.CrossRef
190.
191.
192.
Chizmadzhev YA. The mechanisms of lipid-protein rearrangements during viral infection. Bioelectrochemistry. 2004; 129–36.
193.
194.
Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retrovir. 2001;17:1009–19.PubMedCrossRef
195.
Blanc M, Hsieh WY, Robertson KA, Kropp KA, Forster T, Shui G, et al. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity. 2013;38:106–18.PubMedPubMedCentralCrossRef
196.
197.
Ravnskov U. High cholesterol may protect against infections and atherosclerosis. QJM. 2003;96:927–34.PubMedCrossRef
198.
199.
200.
Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J Intern Med. 2011;269(1):64–73.
201.
202.
Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11:1018–30.PubMedPubMedCentralCrossRef
203.
Tang CHA, Zundell JA, Ranatunga S, Lin C, Nefedova Y, Del Valle JR, et al. Agonist-mediated activation of STING induces apoptosis in malignant B cells. Cancer Res. 2016;76:2137–52.PubMedPubMedCentralCrossRef
204.
205.
Frémond M-L, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D, et al. Efficacy of the janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in three children. J Allergy Clin Immunol. 2016;1:1–4.
206.
207.
Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, et al.. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;1–8. doi:10.​1136/​annrheumdis-2015-208562.
208.
Borba HHL, Wiens A, De Souza TT, Correr CJ, Pontarolo R. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. BioDrugs. 2014;28:211–28.PubMedCrossRef
209.
Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin Ther. 2012;34:1006–22.PubMedCrossRef
210.
Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168–78. doi:10.​1002/​art.​24699.PubMedPubMedCentralCrossRef
211.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–30.PubMedPubMedCentralCrossRef
212.
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–33.PubMedPubMedCentralCrossRef
213.
214.
Jin L, Hill KK, Filak H, Mogan J, Knowles H, Zhang B, et al. MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP. J Immunol. 2011;187:2595–601.PubMedPubMedCentralCrossRef
215.
Hagstrom JE, Ludtke JJ, Bassik MC, Sebestyén MG, Adam S a, Wolff J a. Nuclear import of DNA in digitonin-permeabilized cells. J Cell Sci. 1997;110(Pt 1):2323–31.PubMed
216.
Moore MS, Schwoebel ED. Nuclear import in digitonin-permeabilized cells. Curr Protoc Cell Biol. 2001;5:11.7:11.7.1-11.7.17.
217.
Miyamoto K, Yamashita T, Tsukiyama T, Kitamura N, Minami N, Yamada M, et al. Reversible membrane permeabilization of mammalian cells treated with digitonin and its use for inducing nuclear reprogramming by Xenopus egg extracts. Cloning Stem Cells. 2008;10:535–42. doi:10.​1089/​clo.​2008.​0020.PubMedCrossRef
218.
Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36–48.PubMedCrossRef
219.
Miyabe H, Hyodo M, Nakamura T, Sato Y, Hayakawa Y, Harashima H. A new adjuvant delivery system “cyclic di-GMP/YSK05 liposome” for cancer immunotherapy. J Control Release. 2014;184:20–7.PubMedCrossRef
220.
Nakamura T, Miyabe H, Hyodo M, Sato Y, Hayakawa Y, Harashima H. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J Control Release. 2015;216:149–57.PubMedCrossRef
221.
Lee E, Jang HE, Kang YY, Kim J, Ahn JH, Mok H. Submicron-sized hydrogels incorporating cyclic dinucleotides for selective delivery and elevated cytokine release in macrophages. Acta Biomater. 2016;29:271–81.PubMedCrossRef
Metadata
Title
Regulating STING in health and disease
Authors
Yang Li
Heather L. Wilson
Endre Kiss-Toth
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2017
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/s12950-017-0159-2

Other articles of this Issue 1/2017

Journal of Inflammation 1/2017 Go to the issue

Research

Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs

Research

Successful reduction of inflammatory responses and arachidonic acid–cyclooxygenase 2 pathway in human pulmonary artery endothelial cells by silencing adipocyte fatty acid-binding protein

Research

Resveratrol protects against ICV collagenase-induced neurobehavioral and biochemical deficits

Research

Treatment with 24 h–delayed normo- and hyperbaric oxygenation in severe sepsis induced by cecal ligation and puncture in rats

Commentary

Inflammatory Wnt5A signalling pathways affecting barrier function of human vascular endothelial cells

Short Report

Evaluation of a competitive hepcidin ELISA assay in the differential diagnosis of iron deficiency anaemia with concurrent inflammation and anaemia of inflammation in elderly patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits